Related Experiment Video
Updated: Jun 4, 2025
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
DNAJB4/HLJ1 deficiency sensitizes diethylnitrosamine-induced hepatocarcinogenesis with peritumoral STAT3 activation
Wei-Jia Luo1, Wei-Lun Hsu1, Chih-Yun Lu1
1Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
Environmental chemicals and toxins are known to impact human health and contribute to cancer developments. Among these, genotoxins induce genetic mutations critical for cancer initiation. In the liver, proliferation serves not only as a compensatory mechanism for tissue repair but also as a potential risk factor for the progression of premalignant lesions. The role of Human Liver DnaJ-Like Protein (DNAJB4/HLJ1), a stress-responsive heat shock protein 40, in genotoxin-induced liver carcinogenesis remains unexplored. Using whole-genome transcriptomic analysis, we demonstrate that HLJ1 deficiency in mice results in altered gene signatures enriched in pathways associated with chemically induced liver cancer and IL-6/STAT3 signaling activation. Employing diethylnitrosamine (DEN) as a carcinogen, we further reveal that STAT3 and H2AX phosphorylation induced by short-term DEN treatment are amplified in HLJ1-deficient mice. In long-term DEN experiments, HLJ1 deletion enhances tumor proliferation and progression, accompanied by pronounced STAT3 phosphorylation in normal tissues rather than in tumor regions. The tumor-suppressive role of peritumoral HLJ1 is validated through the transplantation of HLJ1-wildtype B16F1 and LLC cancer cell lines into syngeneic HLJ1-deficient mice, which exhibits an augmented tumorigenic phenotype compared to wildtype controls. This study uncovers a previously unrecognized role of HLJ1 in suppressing liver carcinogenesis via the downregulation of STAT3 signaling in peritumoral normal cells. These findings suggest that HLJ1 reinforcement represents a promising strategy for liver cancer treatment and prevention.
Insights
Human Liver DnaJ-Like Protein (HLJ1) deficiency accelerates liver cancer by activating IL-6/STAT3 signaling. Restoring HLJ1 may prevent and treat liver cancer by downregulating this pathway.
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- Environmental toxins and genotoxins contribute to liver cancer development.
- Cell proliferation in the liver can promote premalignant lesion progression.
- The function of Human Liver DnaJ-Like Protein (DNAJB4/HLJ1) in liver carcinogenesis is unknown.
Purpose of the Study:
- To investigate the role of HLJ1 in genotoxin-induced liver carcinogenesis.
- To explore the molecular mechanisms underlying HLJ1's function in liver cancer.
Main Methods:
- Whole-genome transcriptomic analysis in HLJ1-deficient mice.
- Diethylnitrosamine (DEN) administration for short-term and long-term carcinogenicity studies.
- Cancer cell line transplantation into syngeneic mice.
Main Results:
- HLJ1 deficiency alters gene expression, activating pathways linked to chemically induced liver cancer and IL-6/STAT3 signaling.
- HLJ1-deficient mice exhibit amplified STAT3 and H2AX phosphorylation after DEN treatment.
- HLJ1 deletion promotes tumor proliferation and progression, with STAT3 phosphorylation observed in peritumoral normal tissues.
Conclusions:
- HLJ1 suppresses liver carcinogenesis by downregulating STAT3 signaling in peritumoral normal cells.
- HLJ1 deficiency promotes liver cancer development and progression.
- Enhancing HLJ1 levels could be a therapeutic strategy for liver cancer prevention and treatment.

